Context imageCXCL10 changes are linked to ruxolitinib response
A phase 2 trial studied whether immune signals change alongside repigmentation during ruxolitinib treatment. Sixty adults were assigned to ruxolitinib cream or vehicle for 24 weeks, followed by active treatment.
The Journal of investigative dermatology



